Actuate Therapeutics (ACTU) Enterprise Value (2023 - 2025)

Actuate Therapeutics (ACTU) has reported Enterprise Value for 3 consecutive years, with -$13.2 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Enterprise Value fell 52.28% year-over-year to -$13.2 million; the TTM figure through Dec 2025 stood at -$13.2 million (down 52.28% YoY), while the FY2025 annual figure was -$13.2 million, down 52.28% from the prior year.
• Enterprise Value grew to -$13.2 million in Q4 2025 per ACTU's latest filing, from -$16.9 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$351709.0 in Q2 2024 and bottomed at -$16.9 million in Q3 2025.
• Historically, Enterprise Value has averaged -$8.2 million across 3 years, with a median of -$7.6 million in 2024.
• On a YoY basis, Enterprise Value climbed as much as 25.15% in 2025 and fell as far as 1746.03% in 2025.
• Actuate Therapeutics' Enterprise Value stood at -$3.0 million in 2023, then tumbled by 192.08% to -$8.6 million in 2024, then sank by 52.28% to -$13.2 million in 2025.
• Business Quant data shows ACTU's Enterprise Value at -$13.2 million in Q4 2025, -$16.9 million in Q3 2025, and -$6.5 million in Q2 2025.